Versican Plus DHPPi/L4R - summary of medicine characteristics

Summary of medicine characteristics - Versican Plus DHPPi/L4R

SUMMARY OF PRODUCT CHARACTERISTICS

NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus DHPPi/L4R lyophilisate and suspension for suspension for injection for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

Active substances:

Lyophilisate (live attenuated):	Minimum	Maximum
Canine distemper virus, strain CDV Bio 11/A	103.1 TCID50*	105.1 TCID50
Canine adenovirus Type 2, strain CAV-2 Bio 13	103.6 TCID50*	105.3 TCID50
Canine parvovirus Type 2b, strain CPV-2b Bio 12/B	104.3 TCID50*	106.6 TCID50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15	103.1 TCID50*	105.1 TCID50
Suspension (inactivated): Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 Leptospira interrogans serogroup Canicola	ALR** titre	> 1:51
serovar Canicola, strain MSLB 1090 Leptospira kirschneri serogroup Grippotyphosa	ALR** titre	> 1:51
serovar Grippotyphosa, strain MSLB 1091 Leptospira interrogans serogroup Australis	ALR** titre	> 1:40
serovar Bratislava, strain MSLB 1088	ALR** titre	> 1:51
Rabies virus, strain SAD Vnukovo-32	> 2.0 IU

* Tissue culture infectious dose 50%.

** Antibody micro agglutination-lytic reaction.

International units.

Adjuvant:

Aluminium hydroxide

1.8–2.2 mg.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Lyophilisate and suspension for suspension for injection.

The visual appearance is as follows:

Lyophilisate: spongy matter of white colour.

Suspension: pink colour with fine sediment.

4. CLINICAL PARTICULARS4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

Active immunisation of dogs from 8–9 weeks of age:

– to prevent mortality and clinical signs caused by canine distemper virus,
– to prevent mortality and clinical signs caused by canine adenovirus type 1,
– to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,
– to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus,
– to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
– to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava,
– to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae,
– to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa and
– to prevent mortality, clinical signs and infection caused by rabies virus.

Onset of immunity :

– 2 weeks after a single vaccination from 12 weeks of age for rabies,
– 3 weeks after the first vaccination for CDV, CAV, CPV,
– 3 weeks after completion of the primary course for CPiV and
– 4 weeks after completion of the primary course for Leptospira components.

Duration of immunity :

At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and rabies. The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.

At least one year following the primary vaccination course for canine parainfluenza virus and Leptospira components. Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.

4.3 Contraindications

None.

4.4 Special warnings for each target species

A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Immunological responses to the CDV, CAV and CPV components of the vaccine may be delayed due to maternally derived antibody interference. However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions. In situations where very high maternally derived antibody levels are expected, the vaccination protocol should be planned accordingly.

Vaccinate healthy animals only.

4.5 Special precautions for use

Special precautions for use in animals

Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.

The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated dogs following vaccination, shedding of CPV has been shown for up to 10 days. However, due to the low pathogenicity of these strains, it is not necessary to keep vaccinated dogs separated from nonvaccinated dogs and domestic cats. The vaccine virus strain CPV-2b has not been tested in other carnivores (except dogs and domestic cats) that are known to be susceptible to canine parvoviruses and therefore vaccinated dogs should be separated from them after vaccination.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

A transient swelling (up to 5 cm) may commonly be observed at the injection site following subcutaneous administration in dogs. This can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.

Anorexia and decreased activity are rarely observed.

Hypersensitivity reactions (e.g. gastrointestinal signs such as diarrhoea and vomiting, anaphylaxis, angioedema, dyspnoea, circulatory shock, collapse) may occur rarely. If such a reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Systemic reactions such as lethargy, hyperthermia and general malaise may occur very rarely.

Clinical signs of immune-mediated diseases, such as haemolytic anaemia, thrombocytopenia or polyarthritis have been reported in very rare cases.

The frequency of adverse reactions is defined using the following convention:

– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
– common (more than 1 but less than 10 animals in 100 animals treated)
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.

A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Subcutaneous use.

Dose and route of administration :

Aseptically reconstitute the lyophilisate with the suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Reconstituted vaccine: pink/red, or yellowish colour with slight opalescence.

Primary vaccination scheme :

Two doses of Versican Plus DHPPi/L4R 3–4 weeks apart from 8–9 weeks of age. The second dose should not be given before 12 weeks of age.

Rabies:

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. Therefore, the first dose may be given using Versican Plus DHPPi/L4. In this case the second vaccination with Versican Plus DHPPi/L4R should not be given before 12 weeks.

However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Some animals may also not show titres > 0.5 IU/ml after the primary vaccination. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of > 0.5 lU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres > 0.5 lU/ml).

In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6 weeks old dogs.

Re-vaccination scheme:

A single dose of Versican Plus DHPPi/L4R should be given every 3 years. Annual re-vaccination is required for Parainfluenza and Leptospira components. Therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No other adverse reactions other than those mentioned in section 4.6 were observed after administration of a 10-fold overdose of the vaccine. However, in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine.

4.11 Withdrawal period(s)

Not applicable.

IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Immunologicals for canidae, live and inactivated viral and inactivated bacterial vaccines.

ATC vet code: QI07AJ06.

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2, canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and rabies virus.

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

Lyophilisate :

Trometamol

Edetic Acid

Sucrose

Dextran 70

Suspension :

Sodium chloride

Potassium chloride

Potassium dihydrogen phosphate

Disodium phosphate dodecahydrate

Water for injection

6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after reconstitution according to directions: use immediately.

6.4 Special precautions for storage

Store and transport refrigerated (2°C-8°C).

Do not freeze.

Protect from light.

6.5 Nature and composition of immediate packaging

Type I glass vial containing 1 dose of lyophilisate closed with a bromobutyl rubber stopper and aluminium cap.

Type I glass vial containing 1 ml of suspension closed with a chlorobutyl rubber stopper and aluminium cap.

Pack sizes:

Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of suspension

Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of suspension.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

7. MARKETING AUTHORISATION HOLDER

Zoetis Belgium SA

Rue Laid Burniat 1

1348 Louvain-la-Neuve

BELGIUM

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/14/163/001

EU/2/14/163/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 07/05/2014.

Date of last renewal: 08/04/2019.